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OBJECTIVE — To determine in Canadian children aged 18 years the 1) incidence of type
2 diabetes, medication-induced diabetes, and monogenic diabetes; 2) clinical features of type 2
diabetes; and 3) coexisting morbidity associated with type 2 diabetes at diagnosis.
RESEARCH DESIGN AND METHODS — This Canadian prospective national surveil-
lance study involved a network of pediatricians, pediatric endocrinologists, family physicians,
and adult endocrinologists. Incidence rates were calculated using Canadian Census population
data. Descriptive statistics were used to illustrate demographic and clinical features.
RESULTS — From a population of 7.3 million children, 345 cases of non–type 1 diabetes
were reported. The observed minimum incidence rates of type 2, medication-induced, and
monogenicdiabeteswere1.54,0.4,and0.2casesper100,000childrenaged18yearsperyear,
respectively. On average, children with type 2 diabetes were aged 13.7 years and 8% (19 of 227)
presented before 10 years. Ethnic minorities were overrepresented, but 25% (57 of 227) of
childrenwithtype2diabeteswereCaucasian.Ofchildrenwithtype2diabetes,95%(206of216)
were obese and 37% (43 of 115) had at least one comorbidity at diagnosis.
CONCLUSIONS — This is the ﬁrst prospective national surveillance study in Canada to
report the incidence of type 2 diabetes in children and also the ﬁrst in the world to report the
incidence of medication-induced and monogenic diabetes. Rates of type 2 diabetes were higher
than expected with important regional variation. These results support recommendations that
screening for comorbidity should occur at diagnosis of type 2 diabetes.
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U
ntil recently, childhood diabetes
was predominantly due to autoim-
mune type 1 diabetes (1). The
emergence of type 2 diabetes, medica-
tion-induceddiabetes,andimprovedrec-
ognition of monogenic forms of diabetes
has altered the pediatric diabetes
landscape.
Theincreaseoftype2diabetesinchil-
dren parallels rising rates of childhood
obesity. There are, however, insufﬁcient
population-based data documenting epi-
demiological trends. The only prospec-
tive national surveillance study from the
U.K. estimated the incidence of type 2 di-
abetes to be 0.53 per 100,000 per year in
children 17 years of age (2). A multi-
center population-based study from the
U.S. reported an incidence of 8.1 per
100,000 person-years and 11.8 per
100,000 person-years in children aged
10–14 and 15–19 years, respectively (3).
Remaining data on childhood type 2 dia-
betesarenotpopulation-basedandthere-
fore are limited in their generalizability.
The potential impact of childhood type 2
diabetes on workforce productivity and
health care systems should not be un-
derestimated. The development of dia-
betes-related micro- and macrovascular
complicationsoccursinyoungadulthood
(4,5). Thus, early cardiovascular disease
related to obesity ampliﬁes the morbidity
associatedwithchildhoodtype2diabetes
(6).
There are limited epidemiological
data available on other forms of non–type
1 diabetes. Greenspan et al. (7) reported
that7%ofchildrenwereaffectedbymed-
ication-induceddiabetesafterrenaltrans-
plant and 50% of these children were
obese. Monogenic forms of diabetes ac-
count for 1–5% of all cases of diabetes
(8) with a minimum prevalence of 0.17
per 100,000 reported in children in the
U.K. (9).
Data on pediatric type 2 diabetes in
Canada, although limited to speciﬁc pop-
ulations and geographic regions, indicate
that the prevalence is increasing (10–13).
There are no Canadian data on the inci-
dence of medication-induced or mono-
genic diabetes in children. In this study,
“children” refers to individuals aged 18
years and “non–type 1 diabetes” includes
type 2 diabetes, medication-induced
diabetes, and monogenic diabetes. We
conductedaprospective,nationalsurveil-
lance study in Canadian children aged
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ofnon–type1diabetes,2)clinicalfeatures
of type 2 diabetes at diagnosis, and 3) co-
morbidity associated with type 2 diabetes
at diagnosis.
RESEARCH DESIGN AND
METHODS— We established a na-
tional network of physicians who partic-
ipated in the surveillance study.
Surveillance was conducted in collabora-
tion with the Canadian Pediatric Surveil-
lance Program (CPSP) and the College of
Family Physicians of Canada (CFPC)–
National Research System (NaReS), both
nationally recognized surveillance pro-
grams. The CPSP comprises 90% of
practicing pediatricians in all regions of
Canada and reported an average monthly
response rate of 83% and a detailed ques-
tionnaire response rate of 90% in pre-
vious surveillance studies (14). NaReS, a
network of the CFPC, comprises
14,500 active members and, in surveil-
lance initiatives for inﬂuenza, reported a
response rate of 75.2% (15).
Physician recruitment
AllCanadianpediatriciansparticipatedin
surveillance (n  2,560). Although rare
pediatric conditions are seen only by pe-
diatric practitioners, and most children
with the diagnosis of diabetes are referred
to pediatric physicians, some youth, par-
ticularlywithtype2diabetes,maybeseen
only by family physicians or adult endo-
crinologists. Therefore, innovative to this
CPSP surveillance study was the recruit-
ment of family practitioners and adult en-
docrinologists from across Canada. A
targeted and enriched sample of family
physiciansandnursepractitionerswasre-
cruited into the study. A list of practitio-
ners who self-identiﬁed through the
CFPC as practicing pediatric, adolescent,
Aboriginal, and rural or inner-city medi-
cine in northern Canada or core urban
areas was generated from a database
housed at NaReS (n  2,823). This data-
base includes clinical practice informa-
tion and demographics on 16,000
practicing family physicians in Canada.
The above identiﬁers were chosen to in-
crease the likelihood of including physi-
cians encountering a case of non–type 1
diabetes in a child. A letter was sent to
these practitioners requesting participa-
tion and asking whether they had previ-
ously encountered a case of non–type 1
diabetes in a child. Feasibility allowed the
involvement of 100 family physicians,
and, therefore, those who agreed to par-
ticipate and had previously seen a case of
non–type 1 diabetes in a child in their
practicewereincluded.Adultendocrinol-
ogists from across Canada were identiﬁed
using the Canadian Medical Association
Directory (n  335), and a convenience
sample was generated by accepting all
adultendocrinologistswhoagreedtopar-
ticipate. In total, 98 family physicians, 49
adult endocrinologists, and 2,567 pedia-
tricians participated with geographic rep-
resentationfromacrossCanada(Table1).
Surveillance methodology
Physicians were surveyed for 24 months
between 1 April 2006 and 30 March
2008. All physicians received an intro-
ductory package that included a case def-
inition (16). Physicians were asked to
report new patient cases when there was
uncertaintyaboutthediagnosisandwhen
an initial diagnosis of type 1 diabetes was
revised to non–type 1 diabetes. A
monthly reporting form was mailed out
requiring a “yes” or “no” response to the
identiﬁcation of a new patient. A detailed
questionnaire was subsequently sent to
each physician who reported a new pa-
tient. This questionnaire requested infor-
mationonclinicalpresentation,ethnicity,
family history, laboratory investigations,
treatment, and coexisting comorbidities
(i.e., obesity, hypertension, dyslipidemia,
polycystic ovary syndrome, nonalcoholic
fatty liver disease, and nephropathy).
Laboratory investigations were per-
formed locally and were reported on the
questionnaire. The availability of pancre-
atic antibody levels (i.e., GAD, islet cell,
andinsulinantibodies)variedacrossCan-
ada, but, where possible, were reported
and were included in the analysis. Dupli-
cate reports were identiﬁed by region of
residence, date of birth, sex, and date of
diagnosis. This enabled duplicate cases to
be removed.
Completed questionnaires were re-
viewed independently by three primary
investigators (S.A., J.K.H., and H.J.D.)
and a diagnosis of type 2 diabetes, medi-
cation-induced diabetes, monogenic dia-
betes, or other (i.e., indeterminate or type
1 diabetes) was assigned. In the event of
disagreement, the questionnaire was for-
warded to three pediatric endocrinology
Table 1—Minimum incidence rates of type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children aged <18
years
Regions
Population
estimate*
Incidence rates (per
100,000 children per year)
Total and participating family physicians, pediatricians,
and adult endocrinologists
T2D MID MD
FP Peds AE
T† P T‡ P T‡ P
Canada 7,358,935 1.54 0.4 0.2 31,127 98 2,835 2,567 368 49
Alberta 775,175 0.7 0.15 0.2 3,176 8 353 288 29 4
British Columbia 846,140 1.2 0.2 0.25 4,525 6 304 264 31 5
Manitoba 276,925 12.45 0.9 0.55 1,060 9 139 123 6 3
Ontario 2,720,310 1.7 0.6 0.2 10,656 50 1,131 988 147 17
Quebec 1,549,215 0.55 0.2 0.3 8,147 5 664 662 136 12
Atlantic Provinces§ 1,136,545 0.7 0.2 0.05 2,521 10 188 188 16 8
Saskatchewan 233,900 0.4 0 0 948 10 53 51 3 0
Territories 31,235 0 0 0 94 0 3 3 0 0
*Data from 2006 Canadian Census—Statistics Canada. †Source: Geographic Distribution of Physicians in Canada: Beyond How Many and Where. Ottawa, ON, Canada,
Canadian Institute for Health Information, 2005. ‡Source: Canadian Medical Directory. §Nova Scotia, New Brunswick, Prince Edward Island, Newfoundland, and
Labrador. Northwest Territories, Yukon, and Nunavut. AE, adult endocrinologists; FP, family physicians; MD, monogenic diabetes; MID, medication-induced
diabetes; P, participating; Peds, pediatricians; T, total; T2D, type 2 diabetes.
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to independently assign a diagnosis. A
consensus diagnosis was ascribed to the
case. If no consensus was achieved, the
case was labeled “indeterminate.” All case
patients met the criteria for diabetes as
deﬁned by the Canadian Diabetes Associ-
ation (17). Criteria for the deﬁnition of
each subgroup of non–type 1 diabetes
were based on 1) for type 2 diabetes, the
presence of risk factors as outlined in the
CanadianDiabetesAssociation2003clin-
ical practice guidelines (17) and informa-
tion on clinical presentation obtained
from the detailed questionnaire (i.e.,
presence of obesity and/or absence of
pancreatic autoimmunity on laboratory
testing, and minimal or no insulin re-
quirements); 2) for medication-induced
diabetes,achildreceivingaknowndiabe-
togenic medication at the time of diagno-
sis (e.g., glucocorticoids, L-asparaginase,
cyclosporine, tacrolimus, atypical antip-
sychotics, and anticonvulsants); and 3)
for monogenic diabetes, isolation of at
least one of six different mutations (glu-
cokinase, hepatic nuclear factor [HNF]-
1, HNF-4, HNF-1, insulin promoter
factor-1, and neurogenic differentiation
1/-cell E-box transactivator 2) or family
history of diabetes affecting multiple gen-
erations in an autosomal dominant pat-
tern and negative testing for markers of
pancreatic autoimmunity.
Statistical methodology
An observed “minimum” incidence rate
was calculated as the total number of new
cases of non–type 1 diabetes per year per
100,000 children aged 18 years. Ob-
served minimum incidence of the three
unique categories of non–type 1 diabetes
(type 2 diabetes, medication-induced di-
abetes, and monogenic diabetes) was cal-
culated. This national surveillance study
was designed to capture all new cases of
physician-diagnosed type 2 diabetes,
medication-induced diabetes, and mono-
genicdiabetesinchildrenaged18years
living in Canada. The denominators used
for Canadian incidence estimates and
province-speciﬁc incidence estimates
were derived from 2006 Canadian Cen-
sus estimates (http://www.statcan.gc.ca),
and it was assumed that the estimate re-
mained the same over the 24-month
study period. Denominators for popula-
tion estimates of children belonging to
speciﬁc ethnic groups (Caucasian, Ab-
original, African/Caribbean, and Asian)
were obtained from the most recent Ca-
nadian Census that included these data
(2001)assumingthatthisestimateclosely
approximated the ethnic distribution of
Canadian children aged 18 years in
2006. Population estimates for children
belongingtoHispanic,MiddleEastern,or
mixed ethnicity (n  19) were not avail-
able and therefore were not included. De-
scriptive statistics were used to illustrate
demographicsandclinicalfeaturesoftype
2, medication-induced, and monogenic
diabetes.
Sensitivity analyses for non–type 1
and type 2 diabetes were conducted to
account for the fact that an enriched
subset of family physicians in Canada
participated in this study. Adult endocri-
nologistsreportedonlyfourcasesoverthe
24-month period and therefore were ex-
cluded from the sensitivity analysis. The
“maximum” incidence rate assumed that
each nonparticipating family physician in
Canada saw the same mean number of
incident cases as those participating in
this study. The selected enriched sample
included physicians with a speciﬁc prac-
tice pattern who were located in regions
known to contain a higher prevalence of
children with non–type 1 diabetes; thus,
the maximum incidence rate is probably
an overestimate of the true incidence rate
of non–type 1 and type 2 diabetes in Ca-
nadian children. The “conservative” inci-
dence rate accounts for the enriched
sampleandsoassumedthateachnonpar-
ticipating family physician saw one-
quarter of the incident cases of those
participating.
Ethical considerations
Ethical approval was obtained from the
University of Manitoba Health Research
Ethics Board and The Hospital for Sick
Children.
RESULTS— Over 24 months of sur-
veillance, reporting rates remained con-
sistent with overall response rates of 79%
among pediatricians (including pediatric
endocrinologists)and96and85%among
family physicians and adult endocrinolo-
gists, respectively. A total of 472 cases
were reported, with an average of 14–16
cases per month over the surveillance pe-
riod.Reportingphysiciansfailedtoreturn
40 (8%) questionnaires. Of the case re-
ports, 21 (4%) were duplicates, and 66
(14%) case reports were excluded be-
cause they did not meet the case deﬁni-
tion. Therefore, a total of 345 cases of
non–type 1 diabetes were included for
analysis; 227 cases of type 2 diabetes, 56
cases of medication-induced diabetes,
and 31 cases of monogenic diabetes. The
31remainingcasescouldnotbeclassiﬁed
and were labeled indeterminate. Ten
cases of type 2 diabetes and 9 cases of
monogenic diabetes were revised diag-
noses after an initial diagnosis of type 1
diabetes. Pediatric endocrinologists re-
ported 266 (77%) cases of non–type 1 di-
abetes; general pediatricians, family
physicians,andadultendocrinologistsre-
ported 53 (15%), 22 (7%), and 4 (1%)
casesofnon–type1diabetes,respectively.
Incidence and demographics
The observed minimum incidence of
non–type1diabetesinCanadianchildren
was 2.34 cases per 100,000 children per
year. Sensitivity analysis revealed a maxi-
mumincidenceof52.8casesper100,000
per year and a conservative incidence es-
timate of 15.0 cases per 100,000 children
per year. Table 1 outlines the observed
minimum incidence rates of type 2, med-
ication-induced, and monogenic diabe-
tes. Sensitivity analysis applied to type 2
diabetes alone revealed a maximum inci-
dence of 40.5 cases per 100,000 children
per year and a conservative incidence of
11.3 cases per 100,000 children per year.
Theobservedminimumincidenceoftype
2 diabetes in female and male children
aged 18 years was 2.0 and 1.3 cases per
100,000 per year, respectively. In chil-
dren 10 and 10 years of age, the ob-
servedminimumincidenceratesoftype2
diabetes were 0.27 and 3.1 per 100,000
per year, respectively. The observed min-
imum incidences of type 2 diabetes in
Caucasian (n  5,236,199), Aboriginal
(n  215,831), Asian (n  600,480), and
African/Caribbean (n  148,466) chil-
drenaged18yearswere0.54,23.2,7.7,
and 1.9 cases per 100,000 per year.
Clinical ﬁndings and investigations
at diagnosis
Type 2 diabetes (n  227). The
mean  SD age at diagnosis was 13.7 
2.5 years, and 58% (132 of 227) of pa-
tients were female. Twenty-ﬁve percent
(57 of 227) were Caucasian, 44.1% (100
of 227) were Aboriginal, 10.1% (23 of
227) were African/Caribbean, and 10.1%
(23 of 227) were Asian. The remaining
patients were Hispanic (1.8% [4 of 227]),
Middle Eastern (0.4% [1 of 227]), or of
mixed ethnicity (6.2% [14 of 227]). Of
children with newly diagnosed type 2 di-
abetes, 8% (19 of 227) were 10 years of
age. Within ethnic groups, 11% (11 of
100)ofAboriginal,8.8%(5of57)ofCau-
casian, 8.7% (2 of 23) of Asian, and 4.3%
Canadian surveillance of type 2 diabetes
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presented before 10 years of age. A posi-
tive family history in either a ﬁrst- or sec-
ond-degree relative was reported in 91%
(185 of 203) of children. Clinical features
and comorbidity at diagnosis are shown
in Table 2. The BMI at presentation was
32.1  7.2 kg/m
2 with a BMI Z score of
2.08  0.6. Of children with type 2 dia-
betes, 10% presented in diabetic ketoaci-
dosis (DKA). There was no signiﬁcant
differenceintherateofDKAacrossethnic
groups (P  0.1). Of children with type 2
diabetes,37%(43of115)hadatleastone
comorbidity and 13% (15 of 115) had
three or more comorbidities at diagnosis.
The A1C at diagnosis was 9.6  3.0%
(median 8.7%). Of children with type 2
diabetes who had pancreatic antibodies
measured, 2.1% (2 of 97) had GAD anti-
bodies,0%(0of88)hadisletcellantibod-
ies, and 15.2% (12 of 79) had insulin
antibodies. Patients were initially treated
with lifestyle counseling alone (33% [69
of 211]), lifestyle counseling combined
with insulin (27% [58 of 211]), lifestyle
counseling combined with an oral agent
(22%[46of211]),orlifestylecounseling,
insulin, and an oral agent (16% [33 of
211]).
Medication-induced diabetes (n  56).
Children presented at a mean  SD age
of 13.3  3.5 years; 55% (31 of 56)
were Caucasian and 52% (24 of 46) were
obese. Forty-one percent (22 of 54) were
asymptomatic. Polyuria (51% [28 of 55])
and fatigue (39% [20 of 51]) were the
most common symptoms. The average
A1Catpresentationwas6.61.9%(me-
dian 5.9%). Glucocorticoid therapy was
reported in 98% (55 of 56) of children;
isolated glucocorticoid treatment was re-
ported in 55% (31 of 56) and glucocorti-
coids in combination with tacrolimus,
L-asparaginase, and cyclosporine in 21%
(12 of 56), 16% (9 of 56), and 4% (2 of
56) of children, respectively. Fourteen
percent (7 of 52) of children did not re-
ceive treatment for their diabetes. Life-
style counseling alone (29% [15 of 52]),
insulin therapy alone (29% [15 of 52]),
and a combination of insulin and lifestyle
counseling (29% [15 of 52]) were used at
similar frequencies.
Monogenicdiabetes(n31). Children
presentedatameanSDageof9.86.5
years, and 71% (22 of 31) were Cauca-
sian. The majority were asymptomatic
(61% [19 of 31]). In those with symp-
toms, polyuria (29% [9 of 31]) and poly-
dipsia (28% [8 of 29]) were most
common. Acanthosis nigricans was re-
ported in 7% (2 of 30) of children. The
BMIZscoreatdiagnosiswas0.630.12.
Elevenpercent(2of19)wereoverweight,
and 16% (3 of 19) were obese at presen-
tation.ThemeanA1Catpresentationwas
7.4  2.4% (median 6.7%).
GAD antibodies (n  15) and insulin
antibodies (n  10) were negative in all
children; 14 patients were tested for islet
cell antibodies, and 1 (7%) tested posi-
tive. Results of genetic testing were avail-
able in 16 patients; 7 had glucokinase
mutations (including the child with pos-
itive islet cell antibodies), 2 had HNF-1
mutations,1hadaninsulinpromoterfac-
tor-1mutation,and6hadconﬁrmedneo-
natal diabetes (Kir6.2 mutations [n  3],
mutations involving chromosome 6 [n 
2],andsyndromesassociatedwithneona-
tal diabetes [n  1]). Treatment was not
initiated in 7% (2 of 29) of children. Of
those treated, regimens included insulin
alone(21%[6of29]),lifestylecounseling
alone (55% [16 of 29]), a combination of
insulinandlifestylecounseling(10%[3of
29]), and insulin, an oral hypoglycemic
agent, and lifestyle counseling (7% [2 of
29]). The majority of children (89% [24
of 27]) did not have comorbidity at
diagnosis.
CONCLUSIONS— This is the sec-
ond national surveillance study to report
ontheincidenceoftype2diabetesinchil-
dren and the ﬁrst to report the incidence
and clinical features at presentation of
type 2 diabetes and other forms of non–
type 1 diabetes in Canadian children.
Based on provincial database registries
(13) and historical evidence (10,11), the
incidenceoftype2diabetesinchildrenin
Canada seems to be increasing. Obesity
seemstobethesinglemostimportantrisk
factor for type 2 diabetes, a ﬁnding com-
mon to other studies (2,3). Interestingly,
8%ofchildrenwithtype2diabetesinour
study were 10 years of age at presenta-
tion. In the U.S. SEARCH for Diabetes in
Youth Study, only 3.6% of cases of type 2
diabetes occurred in children 10 years
of age (3), indicating that this may be a
ﬁnding unique to the Canadian popula-
tion. Our results highlight the fact that
pediatric type 2 diabetes is not exclusive
totheadolescentage-groupandcanoccur
in younger children. Similar to other
studies (18), treatment varied consider-
ably, highlighting a need for clinical trials
toidentifyoptimaltreatmentstrategiesfor
pediatric type 2 diabetes.
The overall observed minimum inci-
denceoftype2diabetesinCanadianchil-
drenisthreetimestheratereportedinthe
U.K. (2) and approximately one-quarter
of that of the U.S. for children 10 years
of age (3). Although the observed mini-
mum incidence of type 2 diabetes in Ca-
nadian Caucasian and Asian children is
comparable to that reported by the U.K.,
the incidence in African/Caribbean chil-
dren is twice that of the U.K. (2). Cana-
dian and U.K. incidence estimates are
easily comparable because of similar sur-
veillance methodologies. The SEARCH
study included 10 locations that were
consideredrepresentativeofthemultieth-
nic distribution of the U.S. population.
Differences in U.S. and Canadian esti-
mates may relate to variations in ethnic
distribution and screening practices or a
sampling bias toward sites with higher
proportions of ethnic groups at higher
risk for type 2 diabetes in the SEARCH
study. To our knowledge, ours is the ﬁrst
population-based study to report the na-
tional incidence of medication-induced
and monogenic diabetes.
Canadian Aboriginal children 18
years of age have the highest incidence of
type 2 diabetes and the majority of these
children are from Manitoba, explaining
the20-foldhigherincidencerateoftype2
diabetes in this province. This ﬁnding is
comparable to the U.S., which reports an
incidence of type 2 diabetes in American
Navajo youth aged 10–14 years of 22.4
cases per 100,000 person-years and
39.34 cases per 100,000 person-years in
those aged 15–19 years (19). Interest-
ingly, type 2 diabetes in American Indian
children 10 years of age is rare (19);
Table 2—Clinical features and comorbidity
at diagnosis of type 2 diabetes
Clinical feature Proportion
Asymptomatic 78/225 (35)
Acanthosis nigricans 161/221 (73)
Obesity* 206/216 (95)
Ketosis 46/104 (44)
Diabetic ketoacidosis† 22/220 (10)
Comorbidity
Polycystic ovarian
syndrome 16/132 (12.1)
Dyslipidemia 78/174 (44.8)
Hypertension 58/205 (28.3)
Alanine transferase
90 IU/l or “fatty
liver” on ultrasound 39/176 (22.2)
Micro-/macroalbuminuria 21/148 (14.2)
Data are n (%). n  227. *BMI 95th percentile for
age and sex. †pH 7.35.
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dren, 11 cases (11%) of type 2 diabetes
occurred in children 10 years of age.
Thisﬁndingsuggeststhatclinicalpractice
guidelines on childhood type 2 diabetes
may require revision for selected popula-
tions (20,21). Finally, although Aborigi-
nalchildrenareatthehighestriskfortype
2 diabetes, 50% of clinically diagnosed
type 2 diabetes occurred in non-
Aboriginal children.
The presence of hyperglycemia, keto-
sis, and pancreatic autoimmunity typi-
cally suggests a diagnosis of type 1
diabetes. In this study, 44% of children
with type 2 diabetes presented with keto-
nuria,10%presentedinDKA,andasmall
percentageexhibitedthepresenceofGAD
andinsulinantibodies.Theseﬁndingsare
similar to those reported in the literature
(2,22). The SEARCH study reported that
21.2% of children with clinically diag-
nosed type 2 diabetes were positive for
GAD antibodies (3). There is debate as to
whether these youth have been misclassi-
ﬁed as having type 2 diabetes; however,
clinically they present with “typical” fea-
tures of type 2 diabetes including obesity
and acanthosis nigricans. Furthermore,
they respond quickly to insulin treatment
and can wean off insulin for extended pe-
riodsoftime(23).Therefore,thepresence
of ketonuria and/or pancreatic autoim-
munity does not preclude type 2 diabetes
in the pediatric age-group. Additional
studiesarenecessarytobetterunderstand
the relationship of pancreatic autoimmu-
nity to the etiology and natural history of
diabetes in children.
This study was limited by factors
common to other population-based sur-
veillance studies. Our study generated a
minimum incidence rate of pediatric
non–type1diabetesforthefollowingrea-
sons: 1) children with diabetes seen by
nonparticipating physicians and nonre-
sponders were not captured; 2) classiﬁca-
tion was not possible when case reports
were incomplete; and 3) reporting physi-
cians may not have recognized all chil-
dren with cases of non–type 1 diabetes.
The incidence of type 2 diabetes in
Saskatchewan seems to be low. This may
reﬂect the unique Aboriginal groups and
otherethnicgroupsthatliveinthatregion
of the country. The possibility of low re-
porting rates by pediatricians and family
doctors in that province remains. The
population estimate for Saskatchewan
(233,900) represents only 3% of the total
Canadian population of children 18
years of age, and, therefore, this underes-
timationprobablyhadminimalimpacton
Canadianincidencerates.Aprevioussur-
veillancestudyusingtheCPSPmethodol-
ogy reported cases from 7 of 13 provinces
andterritories,whichrepresented92%of
the Canadian population (24). Second,
our study depended on physician-based
classiﬁcation of diabetes followed by re-
view and classiﬁcation by clinician inves-
tigators. This methodology was similar to
that used in the U.K. where, 1 year after
their initial study, only one case of type 2
diabetes was reclassiﬁed (18). In the
SEARCH study, differentiation of type 1
and type 2 diabetes was based on the di-
agnosis made by reporting physicians
without review of clinical data by study
investigators. Third, obesity-related mor-
bidities such as hypertension and dyslip-
idemia were considered to be present if
thereportingphysicianindicatedassuch;
clinicalorlaboratoryevidencewasnotre-
quested. Last, testing for monogenic dia-
betes is not widely available in Canada.
Patients with a typical family history and
natural history of disease were classiﬁed
as having monogenic diabetes even with-
out conﬁrmed genetic testing. Therefore,
thecalculatedincidenceofmonogenicdi-
abetes may be either an over- or underes-
timate of the true incidence.
Assessment of the completeness of
ascertainment (i.e., capture-recapture
method)usingindependentsourcesofin-
formation(i.e.,prescriptiondataandhos-
pitalization) was not possible because
many children with type 2 diabetes are
not receiving medication and hospitaliza-
tionisrare.Itislikelythatmostnewcases
of non–type 1 diabetes in children were
detected, as almost all Canadian children
with uncommon conditions are referred
to pediatric practitioners. In this study,
92% of cases were reported by pediatri-
cians or pediatric endocrinologists, re-
ﬂecting the model of care for pediatric
chronic disease in Canada. In addition, a
type 2 diabetes registry in Manitoba re-
ports 35–45 new pediatric cases per year
(25), a number that is consistent with our
study results: a total of 69 new cases of
type2diabeteswerereportedinManitoba
over 2 years. In the present study, 75%
of children with type 2 diabetes were re-
portedbyapediatricendocrinologist.Ev-
ery region in Canada is served by a team
specializing in the care, education, and
support of children with diabetes. A par-
ticular strength of this study is that sur-
veillance occurred over a 24-month
period and reporting rates remained con-
sistent over this time period.
A sensitivity analysis was conducted
to account for the small enriched sample
of family physicians who participated in
this study. Pediatricians were excluded
from the sensitivity analysis because par-
ticipation rates were high, the sample was
not enriched, and previous CPSP surveil-
lance studies with similar participation
rates did not require a sensitivity analysis
(24). The maximum and conservative in-
cidence rates were calculated to provide
conﬁdence intervals between which the
trueincidenceofnon–type1diabeteslies.
Last, our response rates of 79–95% were
acceptable for this type of surveillance
study; however, cases could have been
missed because of lack of reporting.
Thisprospectivenationalsurveillance
study for non–type 1 diabetes provides
information on the existing spectrum of
non–type 1 diabetes in Canadian chil-
dren. Until now, the majority of epidemi-
ological data on pediatric type 2 diabetes
originated from Manitoba where virtually
all cases occur in Aboriginal youth. The
results of this study provide a more accu-
rate representation of type 2 diabetes in
Canadian children and provide baseline
incidence data based on Canada’s unique
ethnic, cultural, and geographic charac-
teristics. As rates of type 2 diabetes in-
crease, surveillance information is critical
toinformhealthpolicymakers,tracksuc-
cess of prevention and treatment strate-
gies, and increase awareness among
health care providers.
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